These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

861 related items for PubMed ID: 18485394

  • 1. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
    Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S, Bartoletti R.
    J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
    Pan CW, Shen ZJ, Ding GQ.
    J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
    [Abstract] [Full Text] [Related]

  • 4. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 5. Loss of heterozygosis on IFN-alpha locus is a prognostic indicator of bacillus Calmette-Guerin response for nonmuscle invasive bladder cancer.
    Cai T, Nesi G, Dal Canto M, Tinacci G, Mondaini N, Piazzini M, Geppetti P, Bartoletti R.
    J Urol; 2010 May; 183(5):1738-43. PubMed ID: 20299058
    [Abstract] [Full Text] [Related]

  • 6. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study.
    Ali-El-Dein B, Nabeeh A, Ismail EH, Ghoneim MA.
    J Urol; 1999 Aug; 162(2):339-42. PubMed ID: 10411034
    [Abstract] [Full Text] [Related]

  • 7. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P, European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [Abstract] [Full Text] [Related]

  • 8. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 9. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
    Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA.
    J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621
    [Abstract] [Full Text] [Related]

  • 14. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
    Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R, Leibovitch I.
    J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
    [Abstract] [Full Text] [Related]

  • 15. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K, Tsuchiya N, Habuchi T, Li Z, Akao T, Ohyama C, Sato K, Kato T.
    BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
    [Abstract] [Full Text] [Related]

  • 16. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?
    Damiano R, De Sio M, Quarto G, Di Lorenzo G, Perdonà S, Palumbo IM, Azzarito G, Giugliano F, Autorino R.
    BJU Int; 2009 Sep; 104(5):633-9. PubMed ID: 19298412
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes.
    Liu B, Wang Z, Chen B, Yu J, Zhang P, Ding Q, Zhang Y.
    Cancer Invest; 2006 Mar; 24(2):160-3. PubMed ID: 16537185
    [Abstract] [Full Text] [Related]

  • 19. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T, Järvinen R, Liukkonen T, Rintala E, Boström P, Seppänen M, Tammela T, Hellström P, Aaltomaa S, Leskinen M, Raitanen M, Kaasinen E, FinnBladder Group.
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [Abstract] [Full Text] [Related]

  • 20. Effect of intravesical instillation on performance of uCYT+ test.
    Lodde M, Mian C, Negri G, Vittadello F, Comploj E, Palermo S, Staffler A, Brössner C, Pycha A.
    Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.